Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smarter scans for breast cancer survivors: could personalized imaging catch recurrences earlier?

NCT ID NCT07426510

Diagnosis Sponsor: Umeå University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests whether using more sensitive imaging (like MRI or contrast mammograms) based on a woman's personal risk can detect breast cancer recurrences earlier than standard mammograms. It will involve 2,300 women who had breast-conserving surgery and are at higher risk of recurrence. The goal is to see if personalized surveillance reduces the number of cancers found between scheduled screenings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Risk-stratified imaging surveillance (MRI or contrast-enhanced mammography)
What this could lead to
If successful, this could lead to earlier detection of breast cancer recurrences, potentially improving survival and reducing the need for more aggressive treatments.
What could go wrong
This is a large but early-stage trial that hasn't started recruiting yet. The more sensitive imaging may also increase false alarms and unnecessary biopsies, and it's not yet proven to improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jan 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed primary breast cancer * Treated with breast-conserving surgery with curative intent * Completed primary treatment according to clinical guidelines * Classified as having increased risk of recurrence according to predefined study risk criteria (based on factors such as age, tumor subtype) * Eligible for imaging surveillance * Registered in participating national or regional breast cancer registry * Able to comply with study follow-up procedures Exclusion Criteria: * Previous ipsilateral or contralateral invasive breast cancer within the last 5 years (except index cancer) * Bilateral mastectomy * Known metastatic breast cancer at time of enrollment * Contraindication to contrast agents or MRI (if applicable for assigned arm) * Ongoing pregnancy at time of randomization * Any condition that, in the investigator's judgment, prevents participation in imaging surveillance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.